Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Lantern Pharma launches an AI-powered RADR® module to Predict Activity and Efficacy of Combination Regimens, accelerating clinical trials and supporting its FDA-cleared Phase 1B/2 TNBC study  and offers strong commercial potential.